New drug tested for advanced cancers
NCT ID NCT05240898
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 24 times
Summary
This early-stage study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Maine, 48201-2013, United States
-
Cleveland Clinic,
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Mary Crowley Medical Research Center
Dallas, Texas, 75230, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02906, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 98229, United States
-
South Texas Accelerated Research Therapeutics (START) - Midwest Location
Grand Rapids, Michigan, 49546, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
University of California Irvine Medical Center
Orange, California, 92868, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Yale School of Medicine
New Haven, Connecticut, 06510-3206, United States
Conditions
Explore the condition pages connected to this study.